Evidence map›Paper›PMID 37122725›Full record

ArticleFrontiers in immunology2023

Characterization of a novel

Karamoko Niaré, Timothy Chege, Micha Rosenkranz, Kennedy Mwai, Zoe Saßmannshausen, Dennis Odera, Lydia Nyamako, James Tuju, Tiono Alfred, John N Waitumbi and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. The N-terminal region of malaria vaccine candidatebioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 8 countries.

Karamoko NiaréDepartment of Biochemistry, Cell and Molecular Biology, West African Centre for Cell Biology of Infectious Pathogens, University of Ghana, Accra, Ghana.
Timothy ChegeKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.
Micha RosenkranzCentre for Infectious Diseases, Parasitology, Heidelberg University Hospital, Heidelberg, Germany.
Kennedy MwaiKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.
Zoe SaßmannshausenCentre for Infectious Diseases, Parasitology, Heidelberg University Hospital, Heidelberg, Germany.
Dennis OderaCentre for Infectious Diseases, Parasitology, Heidelberg University Hospital, Heidelberg, Germany.
Lydia NyamakoKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.
James TujuKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.
Tiono AlfredPublic Health Department, Centre National de Recherche et de Formation sur le Paludisme (CNRFP), Ouagadougou, Burkina Faso.
John N WaitumbiBasic Science Laboratory, US Army Medical Research Directorate-Africa/Kenya Medical Research Institute, Kisumu, Kenya.
Bernhards OgutuKenya Medical Research Institute, Centre for Clinical Research, Nairobi, Kenya.
Sodiomon B SirimaGroupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso.
Gordon AwandareDepartment of Biochemistry, Cell and Molecular Biology, West African Centre for Cell Biology of Infectious Pathogens, University of Ghana, Accra, Ghana.
Bourema KouribaMalaria Research and Training Centre (MRTC), Department of Epidemiology of Parasitic Diseases, Faculty of Pharmacy, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Julian C RaynerCambridge Institute for Medical Research, University of Cambridge, Cambridge, United Kingdom.
Faith H A OsierKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.
Kenya Medical Research Institute · KEUniversity Hospital Heidelberg · DEUniversity of Ghana · GHCentre National de Recherche et de Formation sur le Paludisme · BFGroupe de Recherche et d’Action sur le Foncier · BFUnited States Army Medical Research Directorate - Africa · KEUniversity of Bamako · MLUniversity of Cambridge · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Introduction: Detailed analyses of genetic diversity, antigenic variability, protein localization and immunological responses are vital for the prioritization of novel malaria vaccine candidates. Comprehensive approaches to determine the most appropriate antigen variants needed to provide broad protection are challenging and consequently rarely undertaken. Methods: Here, we characterized PF3D7_1136200, which we named Asparagine-Rich Merozoite Antigen (ARMA) based on the analysis of its sequence, localization and immunogenicity. We analyzed IgG and IgM responses against the common variants of ARMA in independent prospective cohort studies in Burkina Faso (N = 228), Kenya (N = 252) and Mali (N = 195) using a custom microarray, Div-KILCHIP. Results: We found a marked population structure between parasites from Africa and Asia. African isolates shared 34 common haplotypes, including a dominant pair although the overall selection pressure was directional (Tajima's D = -2.57; Fu and Li's F = -9.69; P < 0.02). ARMA was localized to the merozoite surface, IgG antibodies induced Fc-mediated degranulation of natural killer cells and strongly inhibited parasite growth in vitro. We found profound serological diversity, but IgG and IgM responses were highly correlated and a hierarchical clustering analysis identified only three major serogroups. Protective IgG and IgM antibodies appeared to target both cross-reactive and distinct epitopes across variants. However, combinations of IgG and IgM antibodies against selected variants were associated with complete protection against clinical episodes of malaria. Discussion: Our systematic strategy exploits genomic data to deduce the handful of antigen variants with the strongest potential to induce broad protection and may be broadly applicable to other complex pathogens for which effective vaccines remain elusive.

Indexed as

Malaria, FalciparumMalaria VaccinesParasitesAnimalsAntigens, ProtozoanAntigens, SurfaceBurkina FasoHumansImmunoglobulin GMerozoitesPlasmodium falciparumProspective StudiesProtozoan ProteinsAntigens, ProtozoanAntigens, SurfaceImmunoglobulin GMalaria VaccinesProtozoan Proteinsantigen diversityARMAIgG and IgM antibodiesPF3D7_1136200Plasmodium falciparum malariaprotein microarrayvaccines

Identifiers

PMID37122725
PMCPMC10140549
OpenAlexW4365515710

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.